Behavioral activation treatment for depression is effective for patients referred from primary care. Could it also be effective for PTSD as well? Read this article to find out more.
Primary care providers face competing demands in a fast-paced environment. Read about a case of neurosyphilis identified in a primary care clinic, demonstrating the importance of longitudinal assessment and teamwork within the collaborative care model.
Would a single same-day behavioral health appointment following a primary care appointment result in improvements in patients' perceptions of mental health treatment? Read this article to find out more.
Irritability in children is a common complaint and can be broadly classified as normal and developmental or abnormal. Due to increased incidence of bipolar disorder diagnosis in children and concerns about inappropriate treatment, there is a need to determine and review how practitioners assess irritability. Thus, this study looked at how primary care versus specialist practitioners assess and treat school-aged children with irritability. Read on to find out more.
Asian Americans have among the lowest rates of mental health service utilization of any racial/ethnic group in the United States, and research has identified stigma as an underlying reason for this. A group from Harvard looked at the impact of self-stigma in 190 Chinese immigrants with MDD. Learn about its effect on both depression scores and quality of life.
Although the voluntary anal insertion of a foreign body (IFB) doesn' t necessarily indicate mental illness, this is the case for many of the patients who present for emergency surgical procedures. This Brief Report reviews the current practices and management for such cases of anal IFB at a single acute hospital.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”
MY ACCOUNT